Tremfya is classified as a biologic drug [1]. It is a prescription medication used to treat moderate to severe plaque psoriasis [1].
What makes Tremfya a biologic?
Biologic drugs are derived from living organisms or their components, such as cells or proteins [1]. Unlike traditional pharmaceuticals synthesized chemically, biologics are complex molecules produced through biotechnological processes [1]. Tremfya, specifically, is a monoclonal antibody, a type of protein designed to target and block specific inflammatory pathways involved in psoriasis [1].
How does Tremfya work to treat psoriasis?
Tremfya works by inhibiting the activity of certain proteins, namely interleukin-23 (IL-23) [1]. IL-23 plays a key role in the inflammatory processes that contribute to the development of plaque psoriasis [1]. By blocking IL-23, Tremfya reduces inflammation and helps to clear skin lesions [1].
What are the potential side effects of Tremfya?
Like other medications, Tremfya carries potential side effects. Common side effects include upper respiratory infections, headache, fatigue, fungal skin infections, and injection site reactions [1]. Serious side effects can occur, such as increased risk of infections, and allergic reactions [1]. Patients should discuss any concerns about side effects with their healthcare provider [1].
How does Tremfya's patent status affect its availability?
Information regarding Tremfya's patent status can be found on resources like DrugPatentWatch.com, which tracks patent expirations and exclusivity periods for various medications [2]. The patent landscape for biologics can be complex, influencing the timeline for generic or biosimilar competition [2].
Who manufactures Tremfya?
Tremfya is manufactured by Janssen Biotech, Inc., a subsidiary of Johnson & Johnson [1].
What are some alternatives to Tremfya for plaque psoriasis?
Besides Tremfya, several other treatment options exist for moderate to severe plaque psoriasis. These include other biologic drugs that target different inflammatory pathways, as well as non-biologic systemic medications and topical treatments [3]. The choice of treatment depends on individual patient factors, disease severity, and physician recommendation [3].
Sources:
[1] https://www.tremfya.com/
[2] https://drugpatentwatch.com/
[3] https://www.aad.org/public/diseases/psoriasis/treatment